REFERENCES
1. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64:73-84.
2. Younossi Z, Tacke F, Arrese M, et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology 2019;69:2672-82.
3. Caines A, Selim R, Salgia R. The Changing global epidemiology of hepatocellular carcinoma. Clin Liver Dis 2020;24:535-47.
4. Piscaglia F, Svegliati-Baroni G, Barchetti A, et al. ; HCC-NAFLD Italian Study Group. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: a multicenter prospective study. Hepatology 2016;63:827-38.
5. Mittal S, Sada YH, El-Serag HB, Kanwal F, Duan Z, et al. Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population. Clin Gastroenterol Hepatol 2015;13:594-601.e1.
6. Than NN, Ghazanfar A, Hodson J, et al. Comparing clinical presentations, treatments and outcomes of hepatocellular carcinoma due to hepatitis C and non-alcoholic fatty liver disease. QJM 2017;110:73-81.
7. Weinmann A, Alt Y, Koch S, et al. Treatment and survival of non-alcoholic steatohepatitis associated hepatocellular carcinoma. BMC Cancer 2015;15:210.
8. Lonardo A, Ballestri S, Chow PKH, Suzuki A. Sex disparity in hepatocellular carcinoma owing to NAFLD and non-NAFLD etiology: epidemiological findings and pathobiological mechanisms. Hepatoma Res 2020;6:83.
9. Golabi P, Rhea L, Henry L, Younossi ZM. Hepatocellular carcinoma and non-alcoholic fatty liver disease. Hepatol Int 2019;13:688-94.
10. Ioannou GN. Epidemiology and risk-stratification of NAFLD-associated HCC. J Hepatol 2021;75:1476-84.
11. Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the american association for the study of liver diseases. Hepatology 2018;68:723-50.
12. Association for the Study of the Liver. Electronic address: [email protected]., European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2018;69:182-236.
13. Omata M, Cheng AL, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int 2017;11:317-70.
14. Chrysavgis L, Giannakodimos I, Diamantopoulou P, Cholongitas E. Non-alcoholic fatty liver disease and hepatocellular carcinoma: clinical challenges of an intriguing link. World J Gastroenterol 2022;28:310-31.
15. Tanaka H. Current role of ultrasound in the diagnosis of hepatocellular carcinoma. J Med Ultrason (2001) 2020;47:239-55.
16. Kutami R, Nakashima Y, Nakashima O, Shiota K, Kojiro M. Pathomorphologic study on the mechanism of fatty change in small hepatocellular carcinoma of humans. J Hepatol 2000;33:282-9.
17. Hussain SM, Terkivatan T, Zondervan PE, et al. Focal nodular hyperplasia: findings at state-of-the-art MR imaging, US, CT, and pathologic analysis. Radiographics 2004;24:3-17; discussion 18.
18. Tochio H, Tomita S, Kudo M, et al. The efferent blood flow of early hepatocellular carcinoma and borderline lesions: demonstration by color Doppler imaging. J Med Ultrason (2001) 2002;29:205-9.
19. Tochio H, Kudo M. Afferent and efferent vessels of premalignant and overt hepatocellular carcinoma: observation by color Doppler imaging. Intervirology 2004;47:144-53.
20. Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med 2014;11:e1001624.
21. Tzartzeva K, Obi J, Rich NE, et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology 2018;154:1706-1718.e1.
22. Del Poggio P, Olmi S, Ciccarese F, et al. ; Italian Liver Cancer (ITA.LI.CA) Group. Factors that affect efficacy of ultrasound surveillance for early stage hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2014;12:1927-33.e2.
23. Kim YY, An C, Kim DY, Aljoqiman KS, Choi JY, Kim MJ. Failure of hepatocellular carcinoma surveillance: inadequate echogenic window and macronodular parenchyma as potential culprits. Ultrasonography 2019;38:311-20.
24. Uppot RN, Sahani DV, Hahn PF, Gervais D, Mueller PR. Impact of obesity on medical imaging and image-guided intervention. AJR Am J Roentgenol 2007;188:433-40.
25. Uppot RN. Technical challenges of imaging & image-guided interventions in obese patients. Br J Radiol 2018;91:20170931.
26. Esfeh JM, Esfeh JM, Hajifathalian K, Ansari-Gilani K. Sensitivity of ultrasound in detecting hepatocellular carcinoma in obese patients compared to explant pathology. Clin Mol Hepatol 2019;26:54-9.
27. Karlas T, Blank V, Böhlig A. Diagnostic value of ultrasound in fatty liver disease. Ultraschall Med 2021;42:128-53.
28. Sinn DH, Yi J, Choi MS, et al. Incidence and risk factors for surveillance failure in patients with regular hepatocellular carcinoma surveillance. Hepatol Int 2013;7:1010-8.
29. Tarantino L, Ambrosino P, Di Minno MN. Contrast-enhanced ultrasound in differentiating malignant from benign portal vein thrombosis in hepatocellular carcinoma. World J Gastroenterol 2015;21:9457-60.
30. Morgan TA, Maturen KE, Dahiya N, Sun MRM, Kamaya A. American College of Radiology Ultrasound Liver Imaging and Reporting Data System (US LI-RADS) Working Group. US LI-RADS: ultrasound liver imaging reporting and data system for screening and surveillance of hepatocellular carcinoma. Abdom Radiol (NY) 2018;43:41-55.
31. Dietrich CF, Nolsøe CP, Barr RG, et al. Guidelines and good clinical practice recommendations for contrast-enhanced ultrasound (CEUS) in the liver-update 2020 WFUMB in cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS. Ultrasound Med Biol 2020;46:2579-604.
32. Jang JY, Kim MY, Jeong SW, et al. Current consensus and guidelines of contrast enhanced ultrasound for the characterization of focal liver lesions. Clin Mol Hepatol 2013;19:1-16.
33. Seitz K, Strobel D. A milestone: approval of CEUS for diagnostic liver imaging in adults and children in the USA. Ultraschall Med 2016;37:229-32.
34. Vogel A, Cervantes A, Chau I, et al. ; ESMO Guidelines Committee. Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018;1;29(Suppl 4):iv238-55.
35. Vogel A, Cervantes A, Chau I, et al. Correction to: “Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up”. Ann Oncol 2019;30:871-3.
36. Zhang J, Yu Y, Li Y, Wei L. Diagnostic value of contrast-enhanced ultrasound in hepatocellular carcinoma: a meta-analysis with evidence from 1998 to 2016. Oncotarget 2017;8:75418-26.
37. Huang Y, Song J, Zheng J, et al. Comparison of hepatic resection combined with intraoperative radiofrequency Ablation, or hepatic resection alone, for hepatocellular carcinoma patients with multifocal tumors meeting the university of California san Francisco (UCSF) criteria: a propensity score-matched analysis. Ann Surg Oncol 2020;27:2334-45.
38. Lyshchik A, Kono Y, Dietrich CF, et al. Contrast-enhanced ultrasound of the liver: technical and lexicon recommendations from the ACR CEUS LI-RADS working group. Abdom Radiol (NY) 2018;43:861-79.
39. Putz FJ, Verloh N, Erlmeier A, et al. Influence of limited examination conditions on contrast-enhanced sonography for characterising liver lesions. Clin Hemorheol Microcirc 2019;71:267-76.
40. Greis C. Technical aspects of contrast-enhanced ultrasound (CEUS) examinations: tips and tricks. Clin Hemorheol Microcirc 2014;58:89-95.
41. Akdoğan E, Yılmaz FG. The role of acoustic radiation force impulse elastography in the differentiation of benign and malignant focal liver masses. Turk J Gastroenterol 2018;29:456-63.
42. Dong Y, Wang WP, Xu Y, et al. Point shear wave speed measurement in differentiating benign and malignant focal liver lesions. Med Ultrason 2017;19:259-64.
43. Wu JP, Shu R, Zhao YZ, et al. Comparison of contrast-enhanced ultrasonography with virtual touch tissue quantification in the evaluation of focal liver lesions. J Clin Ultrasound 2016;44:347-53.
44. Frulio N, Trillaud H, Perez P, et al. Acoustic radiation force impulse (ARFI) and transient elastography (TE) for evaluation of liver fibrosis in HIV-HCV co-infected patients. BMC Infect Dis 2014;14:405.
45. Taimr P, Klompenhouwer AJ, Thomeer MGJ, et al. Can point shear wave elastography differentiate focal nodular hyperplasia from hepatocellular adenoma. J Clin Ultrasound 2018;46:380-5.
46. Hu X, Huang X, Chen H, et al. Diagnostic effect of shear wave elastography imaging for differentiation of malignant liver lesions: a meta-analysis. BMC Gastroenterol 2019;19:60.
47. Hwang JA, Jeong WK, Song KD, Kang KA, Lim HK. 2-D Shear wave elastography for focal lesions in liver phantoms: effects of background stiffness, depth and size of focal lesions on stiffness measurement. Ultrasound Med Biol 2019;45:3261-8.
48. Ferraioli G, Wong VW, Castera L, et al. Liver ultrasound elastography: an update to the world federation for ultrasound in medicine and biology guidelines and recommendations. Ultrasound Med Biol 2018;44:2419-40.
50. Calderaro J, Seraphin TP, Luedde T, Simon TG. Artificial intelligence for the prevention and clinical management of hepatocellular carcinoma. J Hepatol 2022;76:1348-61.
51. Hassan TM, Elmogy M, Sallam ES. Diagnosis of focal liver diseases based on deep learning technique for ultrasound images. Arab J Sci Eng 2017:42,3127-40.
52. Yamakawa M, Shiina T, Nishida N, Kudo M. Computer aided diagnosis system developed for ultrasound diagnosis of liver lesions using deep learning. IEEE ;2019:2330-33.
53. Schmauch B, Herent P, Jehanno P, et al. Diagnosis of focal liver lesions from ultrasound using deep learning. Diagn Interv Imaging 2019;100:227-33.
54. Nishida N, Yamakawa M, Shiina T, et al. ; JSUM A. I. investigators. Artificial intelligence (AI) models for the ultrasonographic diagnosis of liver tumors and comparison of diagnostic accuracies between AI and human experts. J Gastroenterol 2022;57:309-21.
